Literature DB >> 25112662

The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.

Anne-Christine Ruwald1, Valentina Kutyifa2, Martin H Ruwald3, Scott Solomon4, James P Daubert5, Christian Jons6, Andrew Brenyo7, Scott McNitt2, Duc Do8, Kenji Tanabe8, Amin Al-Ahmad8, Paul Wang8, Arthur J Moss2, Wojciech Zareba2.   

Abstract

AIMS: Previous studies on biventricular (BIV) pacing and cardiac resynchronization therapy-defibrillator (CRT-D) efficacy have used arbitrarily chosen BIV pacing percentages, and no study has employed implantable cardioverter defibrillator (ICD) patients as a control group. METHODS AND
RESULTS: Using Kaplan-Meier plots, we estimated the threshold of BIV pacing percentage needed for CRT-D to be superior to ICD on the end-point of heart failure (HF) or death in 1219 left bundle branch block (LBBB) patients in the MADIT-CRT trial. Patients were censored at the time of crossover. In multivariable Cox analyses, no difference was seen in the risk of HF/death between ICD and CRT-D patients with BIV pacing ≤90% [HR = 0.78 (0.47-1.30), P = 0.344], and with increasing BIV pacing the risk of HF/death was decreased [CRT-D BIV 91-96% vs. ICD: HR = 0.63 (0.42-0.94), P = 0.024 and CRT-D BIV ≥97% vs. ICD: HR = 0.32 (0.23-0.44), P < 0.001]. The risk of death alone was reduced by 52% in CRT-D patients with BIV ≥97% (HR = 0.48, P < 0.016), when compared with ICD patients. Within the CRT-D group, for every 1 percentage point increase in BIV pacing, the risk of HF/death and death alone significantly decreased by 6 and 10%, respectively. Increasing BIV pacing percentage was associated with significant reductions in left ventricular volume.
CONCLUSION: In patients with LBBB, who were in sinus rhythm at enrolment, BIV pacing exceeding 90% was associated with a benefit of CRT-D in HF/death when compared with ICD patients. Furthermore, BIV pacing ≥97% was associated with an even further reduction in HF/death, a significant 52% reduction in death alone, and increased reverse remodelling. Clinical trials.gov identifier: NCT00180271. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Biventricular pacing; Cardiac resynchronization therapy; Efficacy; Heart failure and death; Implantable cardioverter defibrillator; Left bundle branch block

Mesh:

Year:  2014        PMID: 25112662     DOI: 10.1093/eurheartj/ehu294

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Cardiac resynchronization therapy and outcomes in patients with left ventricular assist devices: a systematic review and meta-analysis.

Authors:  Dinesh Chandra Voruganti; Alexandros Briasoulis; Mohsan Chaudhry; Paulino Alvarez; Vlad Cotarlan; Jay K Bhama; Michael Giudici
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

2.  Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Authors:  Anne-Christine Ruwald; Mehmet K Aktas; Martin H Ruwald; Valentina Kutyifa; Scott McNitt; Christian Jons; Suneet Mittal; Jonathan S Steinberg; James P Daubert; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-20       Impact factor: 1.468

Review 3.  Atrial fibrillation and conduction system disease: the roles of catheter ablation and permanent pacing.

Authors:  Anand Thiyagarajah; Dennis H Lau; Prashanthan Sanders
Journal:  J Interv Card Electrophysiol       Date:  2018-08-03       Impact factor: 1.900

Review 4.  Cardiac Resynchronization in Patients with Atrial Fibrillation.

Authors:  S Serge Barold; Bengt Herweg
Journal:  J Atr Fibrillation       Date:  2015-12-31

Review 5.  Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

Authors:  Martin H Ruwald
Journal:  J Atr Fibrillation       Date:  2015-06-30

6.  Evaluation of super-responders to cardiac resynchronization therapy in the presence of left bundle branch block and absence of scar in the posterolateral wall of the left ventricle.

Authors:  Izaias Marques de Sá Junior; José Carlos Pachón Mateos; Juan Carlos Pachón Mateos; Remy Nelson Albornoz Vargas
Journal:  Am J Cardiovasc Dis       Date:  2020-04-15

7.  Cardiac Resynchronization Therapy in continuous flow Left Ventricular Assist Device Recipients: A Systematic Review and Meta-analysis from ELECTRAM Investigators.

Authors:  Kuldeep Shah; Vallabh Karpe; Mohit K Turagam; Mahek Shah; Andrea Natale; Rakesh Gopinathannair; Dhanunjaya Lakkireddy; Jalaj Garg
Journal:  J Atr Fibrillation       Date:  2020-12-31

8.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  J Arrhythm       Date:  2016-02-01

9.  Suboptimal biventricular pacing. What is the mechanism?

Authors:  Vern Hsen Tan; Colin Yeo; Kelvin Wong
Journal:  J Arrhythm       Date:  2019-06-01

10.  Novel two-lead cardiac resynchronization therapy system provides equivalent CRT responses with less complications than a conventional three-lead system: Results from the QP ExCELs lead registry.

Authors:  Naushad A Shaik; Michael Drucker; Christopher Pierce; Gabor Z Duray; Shane Gillett; Crystal Miller; Camden Harrell; George Thomas
Journal:  J Cardiovasc Electrophysiol       Date:  2020-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.